EDAP TMS (EDAP) announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Leon Berard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound, HIFU, technology for the treatment of pancreatic tumors. “We are proud to share this noteworthy achievement as part of our on-going commitment to innovation and improving the lives of patients across a diverse spectrum of disease states,” said Ryan Rhodes, Chief Executive Officer of EDAP. “This first treatment milestone is the result of a strong collaboration between our product and clinical development teams as well as our strategic research and clinical partnerships. This demonstrates our on-going technical and clinical leadership in applying focused ultrasound therapy in areas of significant unmet need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDAP:
- EDAP TMS Unveils Promising HIFU Study Results
- EDAP TMS announces publication of results on HIFU
- EDAP TMS announces scientific presentation on feasability of Focal One
- EDAP TMS announces scientific presentation of data comparing Focal One HIFU
- EDAP TMS price target lowered to $5 from $6 at Piper Sandler